<DOC>
	<DOCNO>NCT00386100</DOCNO>
	<brief_summary>This study evaluate longer-term glycemic effect two medicine approve initial treatment type 2 diabetes . The study consist 2 week screen period ( 2 study visit ) , follow 80 week double-blind treatment period ( 11 study visit ) . Also , sub-study include look change bone mineral density ( BMD ) lumbar spine .</brief_summary>
	<brief_title>A Type 2 Diabetes Study Longer-Term Glycemic Effect AVANDAMET vs. Metformin</brief_title>
	<detailed_description>This phase IV , randomize , double-blind , global , multi-centre study . The study consist 2 week screen period follow 80 week double-blind treatment period . Subjects meet eligibility requirement randomize 1:1 ratio , stratify country , gender ( male female ) pre-screening HbA1c ( ≤9 % &gt; 9 ) either MET AVM . When substudy add , new randomization create participate center . Those subject bone sub-study stratified country , gender ( male , premenopausal female , postmenopausal female ) , pre-screening HbA1c ( i.e. , ≤9 % ; &gt; 9 % ) , either MET AVM . At randomization , Visit 3 ( Week 0 ) , subject initiate Dose Level 1 . Treatment AVM initiate dose 4 mg/500 mg titrate maximum total daily dose AVM 8 mg/2000 mg . Treatment MET therapy initiate dose 500 mg titrate maximum daily dose 2000mg .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>The subject provide write informed consent . The subject male female 18 75 year age time prescreening . The subject establish clinical diagnosis type 2 diabetes accord recommend guideline ( e.g. , American Diabetes Association , International Diabetes Federation , World Health Organization , Canadian Diabetes Association , American Association Clinical Endocrinologists ) . The subject currently treat diet exercise , take 2 week antidiabetic monotherapy insulin past 6 month . The subject BMI &gt; 25 kg/m2 prescreening . The subject Quest HbA1c 7.5 % 10.5 % prescreening . The subject fasting capillary blood glucose 126 mg/dL ( 7mmol/L ) , measure site staff week 0 . If subject premenopausal female childbearing potential , agree practice acceptable contraceptive measure ( e.g . oral birth control pill , Norplant , DepoProvera , intrauterine device ( IUD ) , diaphragm spermicide condom spermicide , abstinence ) least 1 month screening , study , 30 day last dose study medication take The subject able willing perform selfmonitoring blood glucose specify protocol . The subject take oral antidiabetic monotherapy insulin 14 day past 6 month . The subject presence clinically significant renal hepatic disease ( serum creatinine 1.5 mg/dL ( 132.6 mol/L ) males 1.4 mg/dL ( 123.8 mol/L ) female ) : ALT , AST , total bilirubin , alkaline phosphatase &gt; 2.5 time upper limit normal ( ULN ) reference range . The subject anemia define hemoglobin concentration &lt; 11g/dL ( 110g/L ) male &lt; 10g/dL ( 100g/L ) female . Presence unstable severe angina , coronary insufficiency New York Heart Association ( NYHA ) class IIIIV congestive heart failure require pharmacologic treatment . The subject systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 90 mmHg The subject chronic disease require intermittent chronic treatment oral , intravenous , intraarticular corticosteroid ( i.e. , use topical , inhaled nasal corticosteroid permit ) . The subject acute chronic metabolic acidosis history diabetic ketoacidosis . The subject clinically significant abnormality judgment investigator make subject unsuitable inclusion study ( e.g. , physical examination , laboratory test , electrocardiogram , etc ) . The subject use investigational agent within 30 day 5 halflives ( whichever longer ) prior prescreening . The subject female lactating , pregnant , plan become pregnant . The subject prior history severe edema medically serious fluid relate event ( e.g. , heart failure ) . The subject history macular edema . The subject significant hypersensitivity ( e.g. , difficulty swallowing , difficulty breathing , tachycardia skin reaction ) TZDs , biguanides , compound similar chemical structure . The subject diagnosis cancer ( squamous , basal cell , cervical cancer insitu ) past 3 year receive treatment cancer . The subject history suspicion drug abuse alcohol abuse within last 6 month . The subject know severe lactose intolerance . The subject willing comply visit procedure describe protocol . The subject disease may affect bone turnover include , limited : Paget 's disease , hypercalcemia , hypocalcemia , hyperparathyroidism , hyperthyroidism , osteomalacia , metastatic bone disease The subject weight great 300 lb ( 136.4 kg ) . The subject receive treatment bisphosphonates ( ≥1 month cumulative treatment within last 12 month ) fluoride ( dose great 10mg/day within previous 5 year ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Fasting Plasma Glucose</keyword>
	<keyword>Dual energy X ray absorptiometry ( DXA )</keyword>
	<keyword>Drug-naive</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Bone Mineral Density</keyword>
	<keyword>Hyperglycemia</keyword>
	<keyword>HbA1c</keyword>
</DOC>